Upgrade to enjoy subscriber-only features like email alerts and data export. See the Plans and Pricing

Serving hundreds of leading biopharmaceutical companies globally:

McKesson
Covington
Dow
Medtronic
Teva
Express Scripts
Harvard Business School
Fuji
Healthtrust

Generated: May 25, 2018

DrugPatentWatch Database Preview

Details for Patent: 7,294,342

« Back to Dashboard

Which drugs does patent 7,294,342 protect, and when does it expire?

Patent 7,294,342 protects ULESFIA and is included in one NDA.
Summary for Patent: 7,294,342
Title:Ectoparasite asphyxiator compositions and methods for their application
Abstract:Water-soluble or water-dispersible, substantially air-impermeable, pharmacologically acceptable, liquid barrier compositions for treating ectoparasite infestations on animal skin and hair, wherein the compositions contain at least one monohydric aralkyl alcohol to prevent the ectoparasites from closing their respiratory systems, and wherein the compositions are free from pesticides.
Inventor(s): Precopio; Michael J (Collegeville, PA)
Assignee: Summers Laboratories, Inc. (Collegeville, PA)
Application Number:10/336,457
Patent Litigation and PTAB cases: See patent lawsuits and PTAB cases for patent 7,294,342
Patent Claim Types:
see list of patent claims
Use; Composition;

Drugs Protected by US Patent 7,294,342

Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Patented / Exclusive Use Patent Submitted
Shionogi Inc ULESFIA benzyl alcohol LOTION;TOPICAL 022129-001 Apr 9, 2009 RX Yes Yes ➤ Try a Free Trial ➤ Try a Free Trial TOPICAL TREATMENT OF LICE INFESTATIONS ➤ Try a Free Trial
Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Patented / Exclusive Use Patent Submitted

This preview shows a limited data set. Subscribe for full access, or try a Free Trial

Non-Orange Book US Patents Family Members for Patent 7,294,342

For Orange Book-listed patents (shown in the main table above) generic applications must certify that the listed patents are expired, invalid, or will not be infringed by generic entry.

The non-Orange Book patents listed below do not require formal certifications, so they do not automatically impede generic entry. Instead, they represent potential opportunities for branded firms to block generic entry through patent infringment challenges.

Patent No. Title Estimated Patent Expiration
6,793,931 Ectoparasite asphyxiator compositions and methods for their applications ➤ Try a Free Trial
Patent No. Title Estimated Patent Expiration

This preview shows a limited data set. Subscribe for full access, or try a Free Trial

For more information try a trial or see the plans and pricing

Serving hundreds of leading biopharmaceutical companies globally:

UBS
McKesson
AstraZeneca
Julphar
Cerilliant
Medtronic
Dow
Johnson and Johnson
Baxter

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.